The net profit of Sanofi, the pharmaceutical concern from France, grew in the third quarter by 10.3% and amounted to 2 billion 300 million euros. The indicator exceeded the experts' forecasts of 2 billion 140 million euros. Revenues for the quarter of 9 billion 400 million euros were also higher than market estimates of 9 billion 300 million euros. Its growth was 6.3%. Sales of the Genzyme division, which produces vaccines and drugs for the treatment of rare diseases, increased by 36.1%. Growth in revenue from the sale of vaccines was 8.2%. Good quarterly results allowed the company to raise the forecast for the current year for the second time in a year. Now, it expects earnings per share for the year to grow by 4-5%.